While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small molecules against key targets in big markets. TERN ...

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases like oncology and obesity, has announced that its ...

Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data showing one of its other candidates induced 5% weight loss in a month. The ...

HOBOKEN, NJ — During the covid pandemic, when people were staying close to home, many took up the pastime of bird-watching. And various species of birds have made the mile-square city their home, ...

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from ...

Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well as evidence the ...